Scientific Reports · 2017 · 24 citations · 44 references
MedicineOncologyPharmacologyCell SignalingDrug DiscoverySignal TransductionLigand BindingPeptide AnalysisPeptide ChemistryPeptide Drug DiscoveryProtein Interaction DomainsBinding AssaysCell-based AssaysDruggable Target DiscoveryInteraction Interface AnalysisPeptide Structure - Activity RelationshipsPhosphatase InhibitionSterile Alpha Motif DomainsTargeting Peptides
The lipid phosphatase Ship2 represents a drug discovery target for the treatment of different diseases, including cancer. Its C-terminal sterile alpha motif domain (Ship2-Sam) associates with the Sam domain from the EphA2 receptor (EphA2-Sam). This interaction is expected to mainly induce pro-oncogenic effects in cells therefore, inhibition of the Ship2-Sam/EphA2-Sam complex may represent an innovative route to discover anti-cancer therapeutics. In the present work, we designed and analyzed several peptide sequences encompassing the interaction interface of EphA2-Sam for Ship2-Sam. Peptide conformational analyses and interaction assays with Ship2-Sam conducted through diverse techniques (CD, NMR, SPR and MST), identified a positively charged penta-amino acid native motif in EphA2-Sam, that once repeated three times in tandem, binds Ship2-Sam. NMR experiments show that the peptide targets the negatively charged binding site of Ship2-Sam for EphA2-Sam. Preliminary in vitro cell-based assays indicate that -at 50 µM concentration- it induces necrosis of PC-3 prostate cancer cells with more cytotoxic effect on cancer cells than on normal dermal fibroblasts. This work represents a pioneering study that opens further opportunities for the development of inhibitors of the Ship2-Sam/EphA2-Sam complex for therapeutic applications.
44
NMR with Proteins and Nucleic Acids
Kurt Wüthrich · Europhysics news · 1986 · 8K citations
Anil Kumar, Richard R. Ernst, Kurt Wüthrich · Biochemical and Biophysical Research Communications · 1980 · 1.9K citations